These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 17631332)

  • 1. Overactive bladder in children. Part 2: Management.
    Franco I
    J Urol; 2007 Sep; 178(3 Pt 1):769-74; discussion 774. PubMed ID: 17631332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overactive bladder in children. Part 1: Pathophysiology.
    Franco I
    J Urol; 2007 Sep; 178(3 Pt 1):761-8; discussion 768. PubMed ID: 17631323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contemporary management of overactive bladder.
    Smith AL; Wein AJ
    Postgrad Med; 2012 Jan; 124(1):104-16. PubMed ID: 22314120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pediatric overactive bladder syndrome: pathophysiology and management.
    Franco I
    Paediatr Drugs; 2007; 9(6):379-90. PubMed ID: 18052408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Update on the second line management of idiopathic overactive bladder].
    Chartier-Kastler E; Castro-Diaz D; De Ridder D; Everaert K; Sievert KD; Spinelli M; van Kerrebroeck P
    Prog Urol; 2009 Sep; 19(8):530-7. PubMed ID: 19699450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current information on sacral neuromodulation and botulinum toxin treatment for refractory idiopathic overactive bladder syndrome: a review.
    Leong RK; De Wachter SG; van Kerrebroeck PE
    Urol Int; 2010; 84(3):245-53. PubMed ID: 20389150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective study of transcutaneous parasacral electrical stimulation for overactive bladder in children: long-term results.
    Lordêlo P; Soares PV; Maciel I; Macedo A; Barroso U
    J Urol; 2009 Dec; 182(6):2900-4. PubMed ID: 19846164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The second-line management of idiopathic overactive bladder: what is the place of sacral neuromodulation and botulinum toxin-A in contemporary practice?
    Chapple C; De Ridder D
    BJU Int; 2009 Nov; 104(9):1188-90. PubMed ID: 19681899
    [No Abstract]   [Full Text] [Related]  

  • 9. [Neuromodulation as a treatment for overactive bladder syndrome].
    Smits MA; Marcelissen TA; van Kerrebroeck PE; de Wachter SG
    Ned Tijdschr Geneeskd; 2012; 156(33):A4135. PubMed ID: 22894803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison between oxybutynin, functional electrical stimulation and pelvic floor training for treatment of detrusor overactivity in women: a review.
    Arruda RM; Castro R; Sartori M; Girão MJ
    Curr Opin Obstet Gynecol; 2009 Oct; 21(5):412-4. PubMed ID: 19593131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of the overactive bladder: a review of pharmacological therapies and methods used by the urological specialist.
    Waine E; Hashim H; Abrams P
    Can J Urol; 2007 Apr; 14(2):3478-88. PubMed ID: 17466152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Re: Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics.
    Cartwright R; Cardozo L
    J Urol; 2007 Feb; 177(2):796-7; author reply 797. PubMed ID: 17222687
    [No Abstract]   [Full Text] [Related]  

  • 13. Management of refractory overactive bladder in adults.
    De E
    Can J Urol; 2008 Dec; 15(6):4388-98. PubMed ID: 19046492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy.
    Giannantoni A; Rossi A; Mearini E; Del Zingaro M; Porena M; Berardelli A
    J Urol; 2009 Oct; 182(4):1453-7. PubMed ID: 19683298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial.
    Peters KM; Macdiarmid SA; Wooldridge LS; Leong FC; Shobeiri SA; Rovner ES; Siegel SW; Tate SB; Jarnagin BK; Rosenblatt PL; Feagins BA
    J Urol; 2009 Sep; 182(3):1055-61. PubMed ID: 19616802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developments in the pharmacotherapy of the overactive bladder.
    Sellers DJ; McKay N
    Curr Opin Urol; 2007 Jul; 17(4):223-30. PubMed ID: 17558263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonneurogenic voiding disorders: what's new?
    Glassberg KI; Combs AJ
    Curr Opin Urol; 2009 Jul; 19(4):412-8. PubMed ID: 19451817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prospective study of the clinical and urodynamic results of intradetrusor botulinum toxin injections for the treatment of neurogenic overactive bladder].
    Bentaleb Y; Castel-Lacanal E; Sallusto F; De Boissezon X; Malavaud B; Marque P; Rischmann P; Gamé X
    Prog Urol; 2008 Jul; 18(7):449-55. PubMed ID: 18602606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overactive bladder: treatment options in primary care medicine.
    Sussman DO
    J Am Osteopath Assoc; 2007 Sep; 107(9):379-85. PubMed ID: 17908830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term efficacy of percutaneous tibial nerve stimulation for different types of lower urinary tract dysfunction in children.
    Capitanucci ML; Camanni D; Demelas F; Mosiello G; Zaccara A; De Gennaro M
    J Urol; 2009 Oct; 182(4 Suppl):2056-61. PubMed ID: 19695611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.